Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Status: Enrolling
Updated:  12/16/2015
North Shore - Long Island Jewish Heath System - Monter Cancer Center
mi
from
New Hyde Park, NY
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Status: Enrolling
Updated: 12/16/2015
North Shore - Long Island Jewish Heath System - Monter Cancer Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Status: Enrolling
Updated:  12/16/2015
Exdeo Clinical Research Inc.
mi
from
Abbotsford,
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Status: Enrolling
Updated: 12/16/2015
Exdeo Clinical Research Inc.
mi
from
Abbotsford,
Click here to add this to my saved trials
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Ucla Department Of Medicine
mi
from
Los Angeles, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Ucla Department Of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Chicago
mi
from
Chicago, IL
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Kansas Medical Center
mi
from
Westwood, KA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Kansas Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Wayne State University
mi
from
Detroit, MI
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
John Theurer Cancer Center
mi
from
Hackensack, NJ
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Oregon Health and Science University
mi
from
Portland, OR
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Local Institution
mi
from
Capital Federal,
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Status: Enrolling
Updated:  12/17/2015
OPKO Renal
mi
from
Bannockburn, IL
Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Status: Enrolling
Updated: 12/17/2015
OPKO Renal
mi
from
Bannockburn, IL
Click here to add this to my saved trials
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated:  12/18/2015
Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie
mi
from
Chicago, IL
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated: 12/18/2015
Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie
mi
from
Chicago, IL
Click here to add this to my saved trials
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated:  12/18/2015
Novartis Investigative Site
mi
from
Barretos,
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated: 12/18/2015
Novartis Investigative Site
mi
from
Barretos,
Click here to add this to my saved trials
Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)
Telehealth Tinnitus Intervention for Patients With TBI
Status: Enrolling
Updated:  12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)
Telehealth Tinnitus Intervention for Patients With TBI
Status: Enrolling
Updated: 12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Working Memory Changes With Aging and Hearing Loss
Effects of Aging and Hearing Loss During Rapid Sound Processing
Status: Enrolling
Updated:  12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Working Memory Changes With Aging and Hearing Loss
Effects of Aging and Hearing Loss During Rapid Sound Processing
Status: Enrolling
Updated: 12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Status: Enrolling
Updated:  12/21/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Status: Enrolling
Updated: 12/21/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated:  12/22/2015
Massachusetts General Hospital
mi
from
Boston, MA
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated: 12/22/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated:  12/22/2015
The University of California Irvine
mi
from
Orange, CA
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated: 12/22/2015
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated:  12/22/2015
The University of California, San Diego
mi
from
La Jolla, CA
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status: Enrolling
Updated: 12/22/2015
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Early Detection of Noise-Induced Hearing Loss
Early Detection of Noise-Induced Hearing Loss
Status: Enrolling
Updated:  12/22/2015
VA Loma Linda Healthcare System, Loma Linda, CA
mi
from
Loma Linda, CA
Early Detection of Noise-Induced Hearing Loss
Early Detection of Noise-Induced Hearing Loss
Status: Enrolling
Updated: 12/22/2015
VA Loma Linda Healthcare System, Loma Linda, CA
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Urology Database to Evaluate Clinical Information and Improve Patient Care.
Urology Database for Outcomes Research
Status: Enrolling
Updated:  12/22/2015
William Beaumont Hospital
mi
from
Royal Oak, MI
Urology Database to Evaluate Clinical Information and Improve Patient Care.
Urology Database for Outcomes Research
Status: Enrolling
Updated: 12/22/2015
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome
Status: Enrolling
Updated:  12/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome
Status: Enrolling
Updated: 12/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
UC Davis Comprehensive Cancer Center LAPS
mi
from
Sacramento, CA
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
UC Davis Comprehensive Cancer Center LAPS
mi
from
Sacramento, CA
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated:  12/23/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Status: Enrolling
Updated: 12/23/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
InFlux System for Nasal Breathing Improvement
Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing
Status: Enrolling
Updated:  12/28/2015
St. Elizabeths Medical Center
mi
from
Boston, MA
InFlux System for Nasal Breathing Improvement
Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing
Status: Enrolling
Updated: 12/28/2015
St. Elizabeths Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
InFlux System for Nasal Breathing Improvement
Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing
Status: Enrolling
Updated:  12/28/2015
Bay Area ENT
mi
from
Ocean Springs, MS
InFlux System for Nasal Breathing Improvement
Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing
Status: Enrolling
Updated: 12/28/2015
Bay Area ENT
mi
from
Ocean Springs, MS
Click here to add this to my saved trials
Scalar Localization Cochlear Electrode Array Using 64 Slice CT
Scalar Localization of Cochlear Implant Electrode Array in Hearing Preservation Patients Using 64 Slice CT
Status: Enrolling
Updated:  12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Scalar Localization Cochlear Electrode Array Using 64 Slice CT
Scalar Localization of Cochlear Implant Electrode Array in Hearing Preservation Patients Using 64 Slice CT
Status: Enrolling
Updated: 12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents
A Pilot Study to Evaluate the Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents
Status: Enrolling
Updated:  12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents
A Pilot Study to Evaluate the Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents
Status: Enrolling
Updated: 12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Status: Enrolling
Updated:  12/31/2015
The Mayo Clinic
mi
from
Rochester, MN
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Status: Enrolling
Updated: 12/31/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation
Enhanced Firefighter Rehab Trial
Status: Enrolling
Updated:  1/4/2016
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation
Enhanced Firefighter Rehab Trial
Status: Enrolling
Updated: 1/4/2016
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Results of Facial Soft Tissue Reconstruction in Patients Who Have Suffered Traumatic Injury
Structural Fat Grafting for Craniofacial Trauma
Status: Enrolling
Updated:  1/4/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
A Study to Evaluate the Results of Facial Soft Tissue Reconstruction in Patients Who Have Suffered Traumatic Injury
Structural Fat Grafting for Craniofacial Trauma
Status: Enrolling
Updated: 1/4/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated:  1/4/2016
Camino Ear, Nose and Throat Clinic
mi
from
San Jose, CA
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated: 1/4/2016
Camino Ear, Nose and Throat Clinic
mi
from
San Jose, CA
Click here to add this to my saved trials
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated:  1/4/2016
EarLens Corporation
mi
from
Menlo Park, CA
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated: 1/4/2016
EarLens Corporation
mi
from
Menlo Park, CA
Click here to add this to my saved trials